Replies to post #15252 on Cdex, Inc. (fka CDEX)

[Crow3]

CDEX

Positives... They have Valimed on the market. Never before have they had anything much on the market except stock.

They have doubled or tripled revenue compared to the past.

Negatives.. They are outa money.

They advertise many things that they ain't got..

It is not hard to double or triple revenue when the revenue is zero or nearly so.

Valimed ain't selling much.

No word if they are making more that the first run of 25, or if BAXA inventory is getting short...

Heck yes, a steal at .38!!!! LOL!!

[d4diddy]

Griffin states that "the reason we've picked 300 beds or larger hospitals is because those hospitals will have a high usage rate of the cuvettes..."

Yeah right, sure it is Griffin, you're targeting the big hospitals just to sell more of the cuvettes and not because very few smaller hospitals can afford to buy a picee of equipment for supplemental quality assurance! LOL

Ya'll best be lowering the price of those things so ALL hospitals can afford 'em, not just the cream-of-the-crop.

It appears as if the price skimming strategy of the newly launched Valimed was short lived. Not enough buyers at the 80K, even a 38% discount doesn't seem to be generating sales.

That's what can happen with a highly niche product, you're assured some sales, not a lot, just some.

Have they learned their lesson? NO! The meth gun will only detect meth at first, then a few other substances later.

Ahura's FirstDefender can detect over 2500 drugs, explosives and haz mats and can do probable analysis on over a million combinations of chemicals. It can see thru glass and plastic containers as well as open air.

How can the meth gun possibly compete? Answer: It detects trace amounts of meth in open air.

Another niche market. Good news, they're guaranteed some sales if it works reliably.